NF2 and neurofibromatosis type 1: Results will inform implementation efforts and future clinical trials in other NF populations (eg, adolescents with NF1 and NF2, parents of children with NF1 and NF2, and adults with NF2 who are deaf) as well as other trials targeting geographically diverse individuals with rare diseases.